Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3mpZiOu
via IFTTT